An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Figure 5. A2-32-01 inhibits ClpP and is cytotoxic to AML cells. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
CitationFull text
Figure 6. ClpP expression correlates with sensitivity to A2-32-01 in primary AML cells. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Figure 2. Knockdown of ClpP reduces the growth and viability of AML cells. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Figure 3. ClpP knockout mice are viable with normal hematopoiesis. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Figure 1. Genetic screen identifies ClpP as essential for the viability of leukemia cells. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Figure 7. A2-32-01 shows anti-AML activity in xenograft models of human leukemia. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Figure 4. ClpP regulates mitochondrial metabolism. From: Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leuekmia.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on